FDA Advisory Panels Against CV Safety Claim for Naproxen FDA Advisory Panels Against CV Safety Claim for Naproxen

With a 16-9 vote, the FDA's AAC and DSARM panel members said the evidence is insufficient to suggest naproxen has a lower cardiovascular risk profile than other NSAIDs. Heartwire
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news